In UK, it's strike 2 for Alzheimer's treatments from Lilly and Biogen/Eisai
After reviewing additional clinical data, England's drug-price watchdog NICE has slapped down Eli Lilly's Kisunla and Biogen and Eisai's Leqembi for a second time, after both were approved by the U.K.’s MHRA.
After reviewing additional clinical data, England's drug-price watchdog NICE has slapped down Eli Lilly's Kisunla and Biogen and Eisai's Leqembi for a second time, after both were approved by the U.K.’s MHRA.
